(Q39094900)

9 September 2017

title

DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft (English)

1 reference

non-small-cell lung carcinoma

9 September 2017

1 reference

1 reference

1 reference

Mao-Fa Zheng

1

1 reference

9 September 2017

Si-yu Shen

series ordinal

2

1 reference

9 September 2017

Wei-da Huang

series ordinal

3

1 reference

9 September 2017

language of work or name

1 reference

17 September 2013

1 reference

Cancer Chemotherapy and Pharmacology

9 September 2017

published in

1 reference

9 September 2017

volume

72

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

1031-1041

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2281-z

9 September 2017

exact match

0 references

cites work

PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

THE METABOLISM OF TUMORS IN THE BODY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Why do cancers have high aerobic glycolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Metabolic targeting as an anticancer strategy: dawn of a new era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Metabolic modulation of glioblastoma with dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Capecitabine-docetaxel combination treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

The cancer stem cell microenvironment and anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Novel cancer stem cell therapy on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2281-Z

10.1007/S00280-013-2281-Z

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference